Introduction
The prevalence of epilepsy, and treatment with antiepileptic drugs (AEDs), is increasing. A large cohort study from UK primary care showed that the prevalence of persons ever diagnosed with epilepsy and prescribed antiepileptic drugs on one or more occasions increased from 0.9% to 1.2% between 1993 and 2007. 1 Prescription of antiepileptic drugs remains the mainstay of seizure prevention in people with epilepsy. 2 Side effects to AEDs, including both dose-related side effects and idiosyncratic adverse drugs reactions, represent an important limiting factor in epilepsy treatment. Older AEDs generally have a less favourable safety profile. 2 Several newer AEDs have now been introduced with the aim of increasing efficacy and reducing side effects. 3, 4 Safety for use in pregnancy is an important concern in younger women. 5 However, these newer drugs are generally more costly because they are not initially available in generic formulations. Initial drug selection is often the responsibility of specialists in neurology, internal medicine, psychiatry, paediatrics or elderly care. Primary care physicians may lack experience in selecting and adjusting the dosage of newer drugs, nevertheless the continuation of antiepilepsy drugs is largely managed by them. Drug utilisation studies in epilepsy serve several purposes. Such studies provide data on the prevalence of exposure to different AEDs in a population with epilepsy in order to inform pharmacoepidemiological and drug safety studies in AEDs. Drug utilisation studies also provide descriptive information on the process of diffusion of newer AEDs into clinical practice in primary care in the UK, as well as quantitative estimates for the decline in prescribing of older AEDs. This information may be used to inform clinical prescribing policies. The present paper therefore reports a descriptive epidemiological study of antiepileptic drug utilisation 
Methods
This cohort study utilised data from family practices in the UK contributing to the UK General Practice Research Database (GPRD) between 1 January 1993 and 15 October 2008. For entry into the GPRD, family practice data must be up to standard (UTS) for research as set out by the GPRD group. Participants were included in the study cohort if they had ever had a recorded diagnosis of epilepsy and also had received one or more prescriptions for AEDs after they were registered with a GPRD practice. Date of onset of epilepsy was defined as the earliest date at which a participant had a recorded diagnosis of epilepsy or prescription of AEDs.
Participant follow-up started on the date of first AED prescription after the later of: date of onset of epilepsy, date of registration with a GPRD practice, date at which the practice began contributing UTS data to GPRD, or 1 January 1993. Participant follow-up was censored if the participant died or transferred out of a GPRD practice, or at the last date at which their practice contributed UTS data to GPRD. Using this definition, participants remained on follow-up after ceasing to receive AED prescriptions.
Treatment was ascertained from recorded prescriptions issued to patients by their family practice. AEDs were identified from the unique product codes that are used to code prescriptions into primary care electronic records. The following categories of medication were used: barbiturates (phenobarbital, phenobarbital sodium, methylphenobarbital); valproates (valproic acid, sodium valproate); phenytoin (phenytoin, phenytoin sodium); fosphenytoin sodium; carbamazepine; oxcarbazepine; topiramate; primidone; ethosuximide; mesuximide; clobazam; clonazepam; gabapentin; pregabalin; vigabatrin; tiagabine; sultiame; zonisamide; beclamide; lamotrigine; lacosamide; levetiracetam; rufinamide; stiripentol. To calculate person-years of exposure to each AED, participants were considered currently treated with an AED for the 90 days following each prescription. Previous analyses show that precise duration of prescription cannot be reconstructed for a significant proportion of GPRD prescriptions. A period of 90 days was established as an average treatment interval from a previous study of participants with diabetes.
To examine trends in AED utilisation we examined both number of concurrent AEDs prescribed and type of AED prescribed for each year between 1993 and 2008. The total number of personyears of follow-up and AED treated follow-up was calculated for each calendar year by age group (0-14, 15-44, 45-64, 65+ years) and gender. For each year, age group and gender category, we then calculated: (1) the number of person-years of treatment with each type of AED; (2) number of person-years of treatment with AED monotherapy, two concurrent AEDs, three concurrent AEDs, and four or more concurrent AEDs. The trends in types and number of AEDs, and AED combinations, prescribed were then presented as a proportion of AED treated person years for all participants and by age and gender.
Results
The cohort of participants included 63,586 participants from 434 family practices. Total follow-up was 361,207 person-years, of which 282,080 person-years were treated with AEDs and 79,126 person-years not treated with AEDs. The median duration that individual participants remained in the study was 4.50 personyears (inter-quartile range (IQR): 1.74, 8.67). The median number of person-years that were AED treated was 2.97 (IQR: 0.98, 6.86), with a median of 0.66 (IQR: 0.14, 2.75) not AED treated. Table 1 gives the characteristics of the participants who were on follow-up at the start of each calendar year from 1993 to 2008. There are fewer years of follow-up in 2008 because GPRD data were only available for part of this year.
Participants were most commonly treated with AED monotherapy, which accounted for 72.6% of person-years of treated follow-up. Participants were treated with two AEDs during 21.9% of person-years of follow-up, three medications for 4.7% of followup and four or more medications for 0.8% of follow-up. The most commonly used medications were carbamazepine, valproates and phenytoin, which were all utilised for greater than 25% of AED treated follow-up (Table 2) . Three medications (mesuximide, beclamide, lacosamide) were not prescribed to any participants during follow-up. An additional four medications (sultiame, rufinamide, fosphenytoin sodium, stiripentol) were used for less than 5 person-years.
There in the use of lamotrigine (2.0% to 17.0%) and to a lesser extent levetiracetam (0% to 8.6%). Among the less commonly prescribed medications vigabatrin declined in use (2.6% to 0.4%), while use increased for topiramate (0% to 3.8%) and gabapentin (0.1% to 3.4%) (Fig. 2) .
In general there were similar trends in AED utilisation for each gender and age group. In each age group, use of lamotrigine and levetiracetam increased and use of phenytoin or barbiturates declined. However, there were also substantial differences in AED utilisation between different age groups and between men and women. In all age groups, carbamazepine and valproates were among the most highly utilised medications throughout 1993 and 2008. However, valproates showed a substantial decline in the later part of the observation period for women aged 15-44, from a peak use of 40.5% in 1999 to 29.5% in 2008.
In all age groups, use of lamotrigine and levetiracetam increased between 1993 and 2008 (Table 3) . Treatment with Lamotrigine was more common in younger age groups, but the pattern of use differed between men and women. In males, treatment with lamotrigine was highest for those aged 0-14 and showed the greatest increase between 1993 and 2008 in this age group. In females, use of lamotrigine showed a particularly large increase between 1993 and 2008 for women aged 15-44. In 1993 just 3.7% of person-years were treated with this AED but by 2008 it was the most commonly used AED in women of this age at 35.4% of person-years. Treatment with levetiracetam was most frequent in males and females aged 15-44 in comparison to other age groups. Treatment with phenytoin or barbiturates declined in all age groups throughout 1993-2008, but treatment with these medications remained much more frequent for those of older age (Table 3) . Table 4 presents data concerning the prescription of combinations of AEDs. In 1993, combinations of two or more AEDs accounted for 28% of treatment episodes. There were 201 distinct combinations of AEDs in use. The most frequent combination was of sodium valproate and carbamazepine with combinations of phenytoin with either barbiturate, carbamazepine or sodium valproate also being commonly used. The proportion of treatment episodes that were accounted for by AED combinations was 28% in 2000 and 34% in 2008. The number of distinct AED combinations in 
Discussion
This study had the strengths of a very large population-based sample drawn from family practices throughout the UK. Previous studies have confirmed the representativeness of the GPRD population and the validity of diagnoses recorded in GPRD. 8, 9 Prescription records within GPRD are considered to be accurate and complete. The study may not have included prescriptions issued by specialists either in hospital clinics or in private practice. However, the majority of long-term prescriptions are issued through primary care in the UK. We restricted the study to prescriptions issued to participants who had been diagnosed with epilepsy. AEDs may also be prescribed for other indications but these were not considered in the present study. A limitation of the data source is that the type of epilepsy cannot generally be determined with confidence from primary care records. The seizure frequency may also be difficult to ascertain reliably. For these reasons, it may be difficult to judge the appropriateness of prescribing at the level of the individual participant. The focus of the present analysis is therefore at the level of aggregated data for the population at risk.
Participants in the study were diagnosed with epilepsy and had received at least one prescription for AED since their registration at the practice. An appreciable proportion of person-time in the cohort was not treated with AEDs. This raises questions concerning the persistence of AED therapy in primary care. It is not clear whether participants were intentionally weaned off AED therapy, or whether there is a substantial level of prescription non-adherence in primary care. We have shown that failure to renew medication prescriptions is a predictor of mortality in epilepsy. 1 This issue requires further investigation in future research studies and practice. Nearly three quarters of participant follow-up was accounted for by prescription of AED monotherapy, with prescription of more than two AEDs accounting for rather less than a quarter of persontime and just over a quarter of treatment episodes. There have been substantial reductions over time in the utilisation of older AEDs including phenytoin and barbiturates and increased utilisation of newer drugs including lamotrigine. These changes were observed earliest in younger participants while utilisation of older AEDs persisted longer in older adults. Gender differences were generally modest. However, there appeared to be a more rapid shift towards newer AEDs in women aged 15-44 years.
The increased range of AEDs available for prescription was associated with a substantial increase in the number of different drug combinations that was prescribed, increasing from 201 in 1993 to 500 in 2008. However, changes in prescribing of AEDs in combination were consistent with overall trends, showing a decline in the use phenytoin, primidone and barbiturates and increasing use of lamotrigine and levetiracetam.
These changes are generally consistent with national recommendations for prescribing in epilepsy that have been current during this period. 2, 6 A recent revision of guidance for epilepsy prescribing in England, 7 recommends 2 first-line AEDs (carbamazepine, lamotrigine) and 3 other alternative monotherapy AEDs (levetiracetam, oxcarbazepine, sodium valproate). Eight AEDs are recommended as adjunctive treatment if monotherapy fails. Failure of adjunctive treatment should lead to the initiation of further specialist advice, where other AEDs may be considered. Several of our observations are substantially inconsistent with these recommendations, including the widespread persistent use of phenytoin, primidone and phenobarbitone, while oxcarbazepine appears to be under-utilised. However, lack of adherence to current prescribing guidelines may sometimes occur when there is satisfactory seizure control on medication initiated many years ago, even though this medication is no longer recommended for first-line treatment.
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